Clinical Application of Botulinum Toxin for Hemifacial Spasm.
botulinum toxin
hemifacial spasm
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
17 Aug 2023
17 Aug 2023
Historique:
received:
30
06
2023
revised:
04
08
2023
accepted:
11
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Hemifacial spasm is typically caused by contact between the facial nerve and blood vessels. Microvascular decompression, a treatment that directly addresses this pathogenesis, is often considered the most effective treatment method. However, surgery is not immediately performed for patients at risk from the surgical treatment, or for those with an unclear diagnosis. In these instances, Botulinum toxin injection can help manage the patient's symptoms. Numerous studies corroborate the effectiveness and safety of Botulinum toxin treatment, with large-scale studies indicating symptom control lasts, on average, around 15 weeks.
Identifiants
pubmed: 37629617
pii: life13081760
doi: 10.3390/life13081760
pmc: PMC10455826
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
World Neurosurg. 2019 Nov;131:e454-e459
pubmed: 31382068
J Drugs Dermatol. 2012 Jan;11(1):38-45
pubmed: 22206075
J Neural Transm (Vienna). 2008;115(4):585-91
pubmed: 17558461
Clin Neurol Neurosurg. 2021 Apr 2;205:106632
pubmed: 33865214
Toxins (Basel). 2020 Apr 22;12(4):
pubmed: 32331272
Neurosurg Rev. 2021 Dec;44(6):3259-3266
pubmed: 33559796
Int J Mol Sci. 2020 Dec 12;21(24):
pubmed: 33322848
Surg Neurol Int. 2016 Apr 01;7(Suppl 8):S201-7
pubmed: 27127708
Eur J Neurol. 2009 Mar;16(3):392-8
pubmed: 19364366
Cochrane Database Syst Rev. 2020 Nov 19;11:CD004899
pubmed: 33211908
Neurology. 2017 Nov 28;89(22):2245-2253
pubmed: 29093068
Graefes Arch Clin Exp Ophthalmol. 1997 Apr;235(4):197-9
pubmed: 9143885
Fortschr Neurol Psychiatr. 2022 Jan;90(1-02):37-41
pubmed: 35021244
Neurol Res. 2015 Feb;37(2):184-8
pubmed: 25034027
J Neurosurg. 2018 Jul 1;:1-7
pubmed: 29979116
Brain Commun. 2020 Nov 18;3(1):fcaa201
pubmed: 33543139
Aesthet Surg J. 2018 Feb 17;38(2):183-191
pubmed: 28200002
Fortschr Neurol Psychiatr. 2017 Apr;85(4):194-198
pubmed: 28437820
Neurol Clin. 2021 Feb;39(1):209-229
pubmed: 33223084
J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):751-7
pubmed: 9647304
Singapore Med J. 1990 Oct;31(5):469-71
pubmed: 2259946
Toxins (Basel). 2021 Dec 09;13(12):
pubmed: 34941718
JRSM Short Rep. 2013 Feb;4(2):10
pubmed: 23476731
J Neurol Sci. 2015 Sep 15;356(1-2):27-31
pubmed: 26111430
Neurosurg Rev. 2016 Jul;39(3):411-8
pubmed: 26876893
J Korean Med Sci. 1993 Oct;8(5):334-40
pubmed: 8305141
Rev Neurol. 2021 Apr 16;72(8):269-282
pubmed: 33851716
Mov Disord. 1997 Nov;12(6):1013-8
pubmed: 9399229
Toxins (Basel). 2018 May 18;10(5):
pubmed: 29783676
Clin Neuropharmacol. 1986;9(5):415-29
pubmed: 3533250
Turk Neurosurg. 2011;21(4):625-9
pubmed: 22194126
Adv Ther. 2022 May;39(5):2025-2034
pubmed: 35266085